Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: RETRACTED ARTICLE: HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395

Fig. 3

CCDC50-S and CCDC50-FL exert opposite tumorigenic effects in vitro and in vivo. a Colony formation assays were conducted in 786-O and OS-RC-2 cells with CCDC50-S/CCDC50-FL overexpression or CCDC50 silence. The presented data are means ± SD in three independent experiments. b EdU incorporation assays were performed in CCDC50-S/CCDC50-FL overexpressed or CCDC50 silenced 786-O and OS-RC-2 cells. The percent of proliferating cells (Red fluorescence) in total cells (blue fluorescence) was calculated. c 786-O and OS-RC-2 cells expressing CCDC50-S/CCDC50-FL or sh-CCDC50 were implemented with MTS assays to assess cell viability. d-e The migration and invasion ability of CCDC50-S/CCDC50-FL or sh-CCDC50 stably transfected 786-O and OS-RC-2 cells was determined by Transwell assays. f OS-RC-2 cells expressing CCDC50-S/CCDC50-FL or sh-CCDC50 and corresponding control plasmids were injected subcutaneously into mice. Isolated tumors were presented and their volume and weight were calculated. g-h CCDC50-S/CCDC50-FL overexpressed or CCDC50 silenced OS-RC-2 cells were injected subcutaneously into mice caudal vein. The lung metastasis imaging and H.E. staining images were presented. Red arrows meant lung metastases

Back to article page